Welcome to our dedicated page for RETINALGENIX TECHNOLOGIES SEC filings (Ticker: RTGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
RetinalGenix Technologies filings document public-company reporting status, financial-statement timing, and governance changes for a developmental-stage company focused on retinal imaging, genetic testing, and pharmacogenetic mapping. The record includes a Form 12b-25 notification related to the timing of its annual report and an 8-K reporting an executive officer resignation, with disclosures centered on reporting obligations, financial statement finalization, and management structure.
Alpine Securities Corporation (RTGN) submitted a Form 144 notice proposing the sale of 4,214,000 common shares via exercise of warrants. The filing shows a recent reported sale by Bayern Capital LLC of 500 common shares on 05/04/2026 for $1,685.90. The issuer is listed at 39 Exchange Place, Salt Lake City, UT, and the securities trade on OTCQB.
RetinalGenix Technologies Inc. reported another quarterly loss and severe liquidity pressure for the quarter ended March 31, 2026. The company generated no revenue and recorded a net loss of $590,489, similar to the prior year period, driven by $262,149 of general and administrative costs, $117,064 of research and development, and $210,016 of stock-based compensation.
Cash fell to just $180 at March 31, 2026 against total liabilities of $2,563,889 and an accumulated deficit of $18,449,106, leaving a significant stockholders’ deficit. Management discloses “substantial doubt” about the company’s ability to continue as a going concern and estimates it needs about $7,000,000 in additional capital to advance its retinal imaging devices, DNA/GPS genetic testing platform, and related AI database toward commercialization. Operations remain heavily supported by related-party Sanovas, which is owed about $830,632. The filing also notes a continuing material weakness in internal control over financial reporting due to lack of segregation of duties.
RetinalGenix Technologies Inc. files its annual report describing a development-stage ophthalmic business with no product revenue and recurring net losses. The company focuses on four pillars: genetic testing, retinal imaging, a patient information database, and repurposed pharmaceutical therapies for dry age-related macular degeneration and Alzheimer’s dementia.
Management plans initial genetic test sales and beta retinal imaging in 2026 and potential commercialization in 2027, but discloses substantial doubt about its ability to continue as a going concern. RetinalGenix estimates it needs about $7 million in additional funding and has recently raised smaller amounts through private stock placements.
RetinalGenix Technologies Inc. reported that its Chief Financial Officer, Michael Cory Zwerling, resigned from his position, effective immediately on March 22, 2026. The company did not provide additional details about the circumstances of his departure or plans for a successor in this report.
RetinalGenix Technologies (RTGN) filed its Q3 2025 10‑Q, reporting no revenue and a smaller quarterly net loss of $568,791 versus $644,291 a year ago. Operating expenses fell to $567,833 on lower R&D and stock‑based compensation, while interest expense was negligible.
Liquidity is strained: cash was $92 at September 30, 2025 against total liabilities of $2,179,731 and a stockholders’ deficit of $(2,172,730). The company discloses “substantial doubt” about its ability to continue as a going concern and is in discussions to raise capital and explore a potential up‑listing. Related‑party payables include $539,052 due to Sanovas as of quarter‑end.
For the nine months, net loss improved to $1,805,468 from $3,453,800 on sharply lower stock‑based compensation. RTGN sold 82,666 shares for $186,000 year‑to‑date and subsequently sold 12,000 shares for $27,000. A material weakness in internal control over financial reporting (lack of segregation of duties) remains. Common shares outstanding were 18,604,961 at November 14, 2025.
RTGN: A shareholder filed a Form 144 notice to sell up to 77,400 common shares with an aggregate market value of $247,680.00. The filing lists Alpine Securities Corporation as broker and targets an approximate sale date of November 10, 2025 on the OTCQB.
The filing notes 18,604,961 shares outstanding. It also discloses prior acquisitions and recent activity: the securities were acquired via warrant exercise dated 09/01/2018, with payment by check on 03/06/2019. Over the past three months, Bayern Capital LLC reported sales of common shares, including 8,000 for $30,718.67 on 10/24/2025, 10,100 for $36,800.27 on 10/27/2025, and 2,500 for $8,063.95 on 10/31/2025.